From the impact of Obamacare to cutting-edge research, biotech buyouts to FDA decisions, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments in health care, and their implications for long-term investors. In this week's edition, the team talks about a potentially landmark Supreme Court ruling, the impact of President Obama's budget on health-care stocks, the next wave of innovation for the pharma industry, and why investors need to pay attention to a small research company from upstate New York.
In the following segment, health-care analyst David Williamson dives into the legal battle between Myriad Genetics and those who question its ability to patent human genes. The Supreme Court is hearing opening arguments, with a decision expected later this summer.
Watch and discover how far the impact of this verdict could reach.
What macro trend was Warren Buffett referring to when he said "this is the tapeworm that's eating at American competitiveness"? Find out in our free report: "What's Really Eating at America's Competitiveness." You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.